$LYCA

Lycia Therapeutics, Inc.

Lycia Therapeutics is a biotechnology company based in South San Francisco, California. It discovers and develops treatments that degrade disease-causing proteins outside cells for autoimmune, inflammatory, and allergic diseases. Its LYTAC platform supports the development of therapies that selectively lower levels of harmful proteins. Programs include LCA-0061 and LCA-0062, which target IgE for allergic diseases, and LCA-0321, designed to degrade antibodies associated with Graves’ disease.

4
0
0
$38.5M
—
Venrock Healthcare Capital Partners III, L.P.
0%
See all $LYCA insider activity →
Med

Evercore ISI initiates Lycia stock with outperform rating

Evercore ISI initiated coverage on Lycia Therapeutics (NASDAQ:LYCA) with an outperform rating and a $43 price target, citing its LYTACs technology. The company's lead program targets IgE, with clinical trials for food allergies and Graves disease. Lycia raised $318 million in its IPO, priced at $18 per share. Jefferies and TD Cowen also initiated coverage with buy ratings and price targets of $50 and unspecified, respectively.

Venrock Healthcare Capital Partners III, L.P. (Koh Bong Y, Shah Nimish P) purchased $224K of LYCA (indirect holdings)

Venrock Healthcare Capital Partners III, L.P. purchased 8,305 indirectly-held shares of Lycia Therapeutics, Inc. (LYCA) at $26.95 ($0.22M total) on 2026-11-02. Filed jointly with VHCP Co-Investment Holdings III, LLC (10% owner), VHCP Management III, LLC (10% owner), Venrock Healthcare Capital Partners EG, L.P. (10% owner), VHCP Management EG, LLC (10% owner), Venrock Healthcare Capital Partners XP, L.P. (10% owner), VHCP Management XP, LLC (10% owner), Koh Bong Y (10% owner) and Shah Nimish P (10% owner).

Venrock Healthcare Capital Partners III, L.P. (Koh Bong Y, Shah Nimish P) purchased $645K of LYCA (indirect holdings)

Venrock Healthcare Capital Partners III, L.P. purchased 25,004 indirectly-held shares of Lycia Therapeutics, Inc. (LYCA) at an average of $25.78 ($25.23–$26.86, $0.64M total) across 5 trades over 2026-10-28 to 2026-10-30. Filed jointly with VHCP Co-Investment Holdings III, LLC (10% owner), VHCP Management III, LLC (10% owner), Venrock Healthcare Capital Partners EG, L.P. (10% owner), VHCP Management EG, LLC (10% owner), Venrock Healthcare Capital Partners XP, L.P. (10% owner), VHCP Management XP, LLC (10% owner), Koh Bong Y (10% owner) and Shah Nimish P (10% owner).

LYCA sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning LYCA (Lycia Therapeutics, Inc.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.

Recent LYCA coverage spans insider activity, financial news and ipo.

In the last 30 days, LYCA insiders filed 12 SEC Form 4 transactions — 12 purchases ($38.5M) and no sales. The most active reporter was Venrock Healthcare Capital Partners III, L.P. with 12 filings.

What's driving LYCA

AlphAI scores every news story that mentions LYCA with an AI model for sentiment and relevance, and aggregates insider trades from Lycia Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $LYCA

Score

Evercore ISI initiates Lycia stock with outperform rating

Evercore ISI initiated coverage on Lycia Therapeutics (NASDAQ:LYCA) with an outperform rating and a $43 price target, citing its LYTACs technology. The company's lead program targets IgE, with clinical trials for food allergies and Graves disease. Lycia raised $318 million in its IPO, priced at $18 per share. Jefferies and TD Cowen also initiated coverage with buy ratings and price targets of $50 and unspecified, respectively.

Venrock Healthcare Capital Partners III, L.P. (Koh Bong Y, Shah Nimish P) purchased $224K of LYCA (indirect holdings)

Venrock Healthcare Capital Partners III, L.P. purchased 8,305 indirectly-held shares of Lycia Therapeutics, Inc. (LYCA) at $26.95 ($0.22M total) on 2026-11-02. Filed jointly with VHCP Co-Investment Holdings III, LLC (10% owner), VHCP Management III, LLC (10% owner), Venrock Healthcare Capital Partners EG, L.P. (10% owner), VHCP Management EG, LLC (10% owner), Venrock Healthcare Capital Partners XP, L.P. (10% owner), VHCP Management XP, LLC (10% owner), Koh Bong Y (10% owner) and Shah Nimish P (10% owner).

Venrock Healthcare Capital Partners III, L.P. (Koh Bong Y, Shah Nimish P) purchased $645K of LYCA (indirect holdings)

Venrock Healthcare Capital Partners III, L.P. purchased 25,004 indirectly-held shares of Lycia Therapeutics, Inc. (LYCA) at an average of $25.78 ($25.23–$26.86, $0.64M total) across 5 trades over 2026-10-28 to 2026-10-30. Filed jointly with VHCP Co-Investment Holdings III, LLC (10% owner), VHCP Management III, LLC (10% owner), Venrock Healthcare Capital Partners EG, L.P. (10% owner), VHCP Management EG, LLC (10% owner), Venrock Healthcare Capital Partners XP, L.P. (10% owner), VHCP Management XP, LLC (10% owner), Koh Bong Y (10% owner) and Shah Nimish P (10% owner).

$LYCAMedAI 8/10

Venrock Healthcare Capital Partners III, L.P. (Koh Bong Y, Shah Nimish P) purchased $37.7M of LYCA (indirect holdings)

Venrock Healthcare Capital Partners III, L.P. purchased 2,045,440 indirectly-held shares of Lycia Therapeutics, Inc. (LYCA) at an average of $18.41 ($18.00–$26.97, $37.65M total) across 6 trades over 2026-10-23 to 2026-10-27. Filed jointly with VHCP Co-Investment Holdings III, LLC (10% owner), VHCP Management III, LLC (10% owner), Venrock Healthcare Capital Partners EG, L.P. (10% owner), VHCP Management EG, LLC (10% owner), Venrock Healthcare Capital Partners XP, L.P. (10% owner), VHCP Management XP, LLC (10% owner), Koh Bong Y (10% owner) and Shah Nimish P (10% owner).

Related tickers